ストックスクリーナーアプリを入手
0.3766
5.83%
-0.0233
アフターアワーズ：
.37
-0.0066
-1.75%
Ensysce Biosciences Inc (ENSC) 最新ニュース
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 Results: EPS beats estimate, sales up 16% vs view - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - Kalkine
Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com
Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa
ENSC|Ensysce Biosciences Inc|Price:0.520|Chg%:-0.004 - TradingKey
Ensysce completes Cy Biopharma acquisition, raises $21.5 million By Investing.com - Investing.com Australia
Ensysce Biosciences Acquires Cy Biopharma in Deal Backed by Up to $77 Million Financing - citybiz
Thursday's session: most active stocks - ChartMill
Ensysce Biosciences completes acquisition of Cy Biopharma - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition - AllSci
Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package - Quiver Quantitative
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Ensysce completes Cy Biopharma acquisition, raises $21.5 million - Investing.com
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - Barchart.com
Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold - TechStock²
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why is Ensysce Biosciences stock surging today? By Investing.com - Investing.com Canada
Why is Ensysce Biosciences stock surging today? - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Ensysce lands $5.3M grant, completing $15.1M NIDA opioid-safety award - Dealroom
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences Inc (ENSC) Cash Flow - TradingKey
ENSC|Ensysce Biosciences Inc|Price:0.255|Chg%:-0.006 - TradingKey
Ensysce Biosciences Inc (ENSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ensysce Biosciences Inc (ENSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ensysce Biosciences (ENSC) Tests Support at $0.27 After Minor DeclineSMA Signal - dars.gov.et
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences (ENSC) Inches Higher, Testing Near-Term Resistance at $0.29AAII Neutral - dars.gov.et
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026 - TradingView
COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10 - Stock Titan
Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026 - marketscreener.com
Ensysce Biosciences Awarded $5.3 Million To Advance Overdose-Protected Opioid - Pulse 2.0
Ensysce receives $5.3M NIDA award for opioid overdose therapy By Investing.com - Investing.com Nigeria
Ensysce receives $5.3M NIDA award for opioid overdose therapy - Investing.com
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development - Yahoo Finance
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Weatherford Democrat
Federal funds back Ensysce opioid technology designed to limit overdose - Stock Titan
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - Yahoo Finance Singapore
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):